SCHEMBL951666

SCHEMBL951666

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(C(=O)NCCN)CC[C@@H]12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.69
CYP3A4 P08684 7/20 0.69
ALDH1A1 P00352 6/20 0.69
SMN1; SMN2 Q16637 5/20 0.69
MAPT P10636 5/20 0.69
MAPK1 P28482 4/20 0.69
TSHR P16473 4/20 0.69
SHBG P04278 4/20 0.69
SERPINA6 P08185 4/20 0.69
NR3C1 P04150 4/20 0.69
PGR P06401 4/20 0.69
AR P10275 3/20 0.69
GPBAR1 Q8TDU6 3/20 0.69
SIGMAR1 Q99720 3/20 0.69
CYP2C9 P11712 2/20 0.69
HIF1A Q16665 2/20 0.69
ABCB11 O95342 2/20 0.69
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
NR3C2 P08235 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12911353 1.00 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL951668 1.00 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL950022 0.90 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL5692658 0.90 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL950018 0.90 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL950020 0.90 LMNA (0.69) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL22732246 0.86 LMNA (0.84) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL8994121 0.85 LMNA (0.68) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL8994126 0.85 LMNA (0.68) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT
SCHEMBL12945873 0.85 LMNA (0.62) LMNACYP3A4ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1649283-B1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LTD (GB) 2014-06-18 EP disclosed
US-8334387-B2 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2012-12-18 US disclosed
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY GE HEALTHCARE UK LIMITED (GB) 2011-01-20 US disclosed
US-7829714-B2 Method for measuring aromatase activity GE HEALTHCARE LIMITED (GB) 2010-11-09 US disclosed
US-20070184429-A1 Method for measuring aromatase activity GE HEALTHCARE UK LIMITED (GB) 2007-08-09 US disclosed
EP-1649283-A2 METHOD FOR MEASURING AROMATASE ACTIVITY GE Healthcare UK Limited (GB) 2006-04-26 EP disclosed
WO-2005012901-A2 METHOD FOR MEASURING AROMATASE ACTIVITY AMERSHAM BIOSCIENCES UK LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014641-A1 METHOD FOR MEASURING AROMATASE ACTIVITY CYP19A1, CYP17A1, CYP21A2 LMNA 3224/4885CYP3A4 62/4885ALDH1A1 223/4885
US-20070184429-A1 Method for measuring aromatase activity CYP19A1, CYP17A1, CYP21A2 LMNA 3224/4885CYP3A4 62/4885ALDH1A1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.